Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Biotech Stock Drops on FDA Update
10:53am, Wednesday, 24'th May 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) is gaining some attention in the biotech realm today.
2 Under-the-Radar Biotech Stocks to Buy in 2023
09:53am, Wednesday, 24'th May 2023
Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
Sarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy.
09:26am, Wednesday, 24'th May 2023
Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning out.
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
09:04am, Wednesday, 24'th May 2023
The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble. The post Sarepta Therapeutics Dives On An Unexpected Hold-Up
FDA defers decision for Sarepta's gene therapy to June 22
08:17am, Wednesday, 24'th May 2023
The U.S. Food and Drug Administration has deferred its decision on an accelerated approval for Sarepta Therapeutics Inc's gene therapy for a muscle wasting disorder called Duchenne muscular dystrophy
Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophy
08:15am, Wednesday, 24'th May 2023
Sarepta Therapeutics Inc. SRPT, -1.45% said Wednesday that the U.S. Food and Drug Administration has indicated after talks with the company that it's working toward granting accelerated approval of SR
Why These 3 Nasdaq Stocks Buckled Today
03:42pm, Tuesday, 16'th May 2023
The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape to
Sarepta Therapeutics: A Virtual Monopoly In Duchenne Muscular Dystrophy
03:07pm, Tuesday, 16'th May 2023
Last week, an FDA advisory committee voted in favor of approving Sarepta Therapeutics, Inc.'s SRP-9001 for treating DMD. Sarepta Therapeutics stock has good near-term momentum as the BLA is scheduled
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
06:33am, Tuesday, 16'th May 2023
Sarepta Therapeutics Inc. NASDAQ: SRPT jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company's experimental gene therapy to treat Duchenne muscula
FDA board votes to approve gene therapy for Duchenne muscular dystrophy
06:31pm, Monday, 15'th May 2023
David Nierengarten, Wedbush Securities managing director, joins 'Closing Bell Overtime' to discuss Sarepta shares after the FDA panel votes to approve gene therapy for Duchenne muscular dystrophy.
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
02:27pm, Monday, 15'th May 2023
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
Why Is Sarepta (SRPT) Stock Up 29% Today?
11:47am, Monday, 15'th May 2023
Sarepta (NASDAQ: SRPT ) stock is on the move Monday as investors react to news of FDA advisors voting on its gene therapy for Duchenne muscular dystrophy. The big news here is the FDA advisors voting
Sarepta Therapeutics shares soar on FDA panel's support for muscular dystrophy therapeutic
11:03am, Monday, 15'th May 2023
Sarepta Therapeutics shares added almost 25% on Monday morning after the US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee voted eight to six in favor of the
Why Sarepta Therapeutics Stock Is Skyrocketing Today
10:59am, Monday, 15'th May 2023
An FDA advisory committee voted 8-6 in favor of accelerated approval for SRP-9001. The FDA doesn't have to go along with the advisory committee's recommendation, but usually does.
2 Supercharged Growth Stocks to Buy Right Now
04:00pm, Sunday, 14'th May 2023
Growth stocks have been top-performers during the first five months of 2023. This broad-based rally is in danger of stalling because of numerous storm clouds on the horizon.
